Similarly, tumor biopsies demonstrating an “inflamed” phenotype with high numbers of tumor-infiltrating T cells, high expression of PD-L1 on tumor cells, and PD1 expression on infiltrating T cells have all been reported to be associated with clinical responses to pembrolizumab [3, 40–44]. The gene discussed is CD274; the disease is neoplasm.